AmfAR Partners With CytoDyn to Expand HIV Cure Strategy
December 02, 2020
December 02, 2020
NEW YORK, Dec. 2 -- The American Foundation for AIDS Research issued the following news release on Dec. 1:
amfAR, The Foundation for AIDS Research, today announced it had signed an agreement with CytoDyn, a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a compound that may have the potential to advance efforts to develop a cure for HIV. The partnership will support testing the ability of Vyrologix to contribute to an HIV cure in stem cell transplant reci . . .
amfAR, The Foundation for AIDS Research, today announced it had signed an agreement with CytoDyn, a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a compound that may have the potential to advance efforts to develop a cure for HIV. The partnership will support testing the ability of Vyrologix to contribute to an HIV cure in stem cell transplant reci . . .